Low-dose IL-2 therapy is also being considered as a possible therapy for primary Sjögren’s syndrome because of its capacity to expand the T regulatory cell population56,57; however, IL-2 can also have the undesirable effect of activating T cells and perpetuating the effector arm of a T-cell-driven response. This evidence concerns the gene IL2 and Sjogren syndrome.